New Strong Sell Stocks for October 9th
ACH, ARDX and DPRO have been added to the Zacks Rank #5 (Strong Sell) List on October 9th, 2026.
New Strong Sell Stocks for October 6th
VLVLY, ACH and CCJ have been added to the Zacks Rank #5 (Strong Sell) List on October 6th, 2026.
Accendra Health, Inc. (ACH) Q2 2026 Earnings Call Transcript
Accendra Health, Inc. (ACH) Q2 2026 Earnings Call Transcript
Is the Options Market Predicting a Spike in Accendra Health Stock?
Investors need to pay close attention to ACH stock based on the movements in the options market lately.
Accendra Health Makes Progress Addressing Its Debt Load
Accendra Health, Inc. is undergoing a multiyear turnaround, focusing on at-home medicine after divesting its hospital supply unit and cleaning up its balance sheet. ACH's recent refinancing extends maturities, reduces gross debt by ~$100 million, and provides a liquidity runway, enhancing the probability of successful long-term deleveraging. Management reaffirmed full-year guidance, but ongoing margin pressure and slow volume growth mean EBITDA will likely be at the lower end of the outlook.
Is the Options Market Predicting a Spike in Accendra Health Stock?
Investors need to pay close attention to Accendra Health stock based on the movements in the options market lately.
Accendra Health: Debt Reduction Creates Long-Term Opportunity (Upgrade)
Accendra Health is upgraded to "Buy" after severe underperformance, trading at just 2x 2027 free cash flow. ACH faces significant margin pressure and a challenging balance sheet, with net leverage expected at 4.9-5x by end-2026. 2026 is likely a trough year due to a major contract loss; growth is expected to resume in 2027, aided by UnitedHealth volumes.
